Clinical Trial Update: Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of orteronel for metastatic castration-resistant prostate cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• TAK-700 (Orteronel)

Snippet

Sponsor: University of Southern California | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-08-31